A Randomized, Blinded, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Ascending Doses of MEDI0382 in Non-diabetic Obese Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors MedImmune
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 25 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2019 Planned End Date changed from 26 Aug 2019 to 27 Aug 2019.